ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)

HKD 5.05

(0.0%)

Total Debt Summary of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s latest annual total debt in 2023 was 74.77 Million CNY , up 411.48% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s latest quarterly total debt in 2024 Q2 was 85.99 Million CNY , up 13.63% from previous quarter.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported annual total debt of 14.61 Million CNY in 2022, down -21.14% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported annual total debt of 18.53 Million CNY in 2021, down 0.0% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported quarterly total debt of 85.99 Million CNY for 2024 Q2, up 13.63% from previous quarter.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported quarterly total debt of 74.77 Million CNY for 2023 Q4, up 6.25% from previous quarter.

Annual Total Debt Chart of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2023 - 2021)

Historical Annual Total Debt of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2023 - 2021)

Year Total Debt Total Debt Growth
2023 74.77 Million CNY 411.48%
2022 14.61 Million CNY -21.14%
2021 18.53 Million CNY 0.0%

Peer Total Debt Comparison of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Name Total Debt Total Debt Difference
Uni-Bio Science Group Limited 52.86 Million HKD -41.436%
CK Life Sciences Int'l., (Holdings) Inc. 5.93 Billion HKD 98.739%